PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext Growth: ALMKT) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that Jeong Kim, M.D., and the Endoscopy Institute of Hawaii (EIH) clinical team have completed more than 1,200 Cellvizio procedures for the diagnosis and interventional treatment of gastric disease, a condition which can lead to gastric cancer. EIH is part of the Covenant Physician Partners network of facilities and physicians which operates more than 85 leading healthcare centers across the United States.
“With Cellvizio as a key adjunctive tool in my diagnostic arsenal, I am able to provide a thorough screening of the stomach in a relatively short period of time,” said Dr. Kim. “This significantly improves my detection rate of gastric intestinal metaplasia (GIM) and related conditions, while better informing my interventional treatment plan for each patient.”
Dr. Kim, the lead gastroenterologist at EIH, is a specialist providing care for a broad range of digestive illnesses such as detection of stomach and colon cancer, gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and liver disease. His focus on minimally invasive endoscopy led Dr. Kim to add the Cellvizio program to his facility in January 2020. Since then, he has used Cellvizio on more than 1,200 patients, primarily for the screening and detection of GIM, which is a known precursor to gastric cancer and is highly prevalent in certain populations such as patients of Asian descent and among patients with specific risk factors like diet, lifestyle, or family history of gastric disease.
“We’re immensely proud that leading physicians like Dr. Kim are using Cellvizio to advance the diagnostic capabilities for people with gastric disease and to create personalized treatment plans that lead to better patient and practice outcomes,” said Sacha Loiseau, Ph.D., CEO of Mauna Kea Technologies. “This milestone with EIH exemplifies the adoption rate we’ve been seeing for Cellvizio in specialized care centers. We’re looking forward to more and more of these centers coming online thanks to our well executed targeting strategy and solid clinical support.”
Mapping GIM is a burdensome clinical challenge, given the large size of the stomach and the need to adequately visualize the gastric mucosa to rule out suspicious lesions and determine GIM extent. Dr. Kim has developed his own adjunctive protocol used in tandem with the standard protocol to provide the best care to his patients. His total procedure time takes only 10 to 12 minutes for a full visual inspection with Cellvizio, including completing multiple gastric biopsies using the Sydney Protocol.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 3 of Mauna Kea Technologies' 2022 Universal Registration Document filed with the Autorité des marchés financiers (AMF) on June 28, 2023 under number D-23-0545, which is available on the Company's website (www.maunakeatech.com), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.